Abstract: A system having patient image processing capability and being in compliance with health insurance portability and accountability act including a N-server having a database, wherein the N-server receives patient data in a form of numerical values from at least one sender and wherein the patient data is converted into numerical values prior to being sent to the N-server. Additionally, the system includes one or more artificial intelligence program to analyze the data in the form of numerical values and detect patterns for a predefined abnormality.

Abstract: The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of ErbB4.

Abstract: The invention provides compositions and methods for delivering carbon monoxide (CO) to subjects suffering from inflammatory, cardiovascular, Sickle Cell, and other disease. The compositions are liquids, including Newtonian and non-Newtonian liquids, such as pastes, gels, foams, emulsions, and other non-gaseous compositions, in which CO is dissolved at an amount that, when administered to a patient, provides a therapeutically or prophylactically effective amount of CO to the patient. The compositions can be provided in many forms, including in bottles or cans.

Abstract: Provided herein are methods and compositions for treating disease-states associated with presence of increased number of ErbB4+ pro-inflammatory macrophages in a subject in need thereof. The methods include providing an activator of ErbB4 and administering a therapeutically effective amount of the activator to the subject. The compositions include an activator of ErbB4. In one embodiment, the activation of ErbB4 is Neuregulin-4.

Abstract: The invention relates to a novel drug delivery vehicle. Various embodiments of the invention provide a hybrid polymerized liposomal nanoparticle comprising both polymerizable lipids and non-polymerizable lipids. Therapeutic agents can be loaded into the polymerized liposomal nanoparticle and targeting agents can be conjugated to the surface of the polymerized liposomal nanoparticle. Also described in the invention are methods, compositions and kits that utilize the hybrid polymerized liposomal nanoparticle to treat disease conditions such as various cancers.

Abstract: The invention relates to a novel drug delivery vehicle. Various embodiments of the invention provide a hybrid polymerized liposomal nanoparticle comprising both polymerizable lipids and non-polymerizable lipids. Therapeutic agents can be loaded into the polymerized liposomal nanoparticle and targeting agents can be conjugated to the surface of the polymerized liposomal nanoparticle. Also described in the invention are methods, compositions and kits that utilize the hybrid polymerized liposomal nanoparticle to treat disease conditions such as various cancers.

Abstract: The invention relates methods of using a retinoid agonist and a G-CSF or an analog thereof to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of a condition in a subject. The retinoid agonist and the G-CSF or the analog thereof may be provided in a single composition or in separate compositions. A therapeutically effective amount of the retinoid agonist and the G-CSF or the analog thereof may be administered to the subject concurrently or sequentially. Conditions treatable with the methods and compositions include but are not limited to various forms of neutropenia and microbial infections. The invention also relates to methods for determining the efficacy of the treatments described herein.

Abstract: The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of ErbB4.

Abstract: Provided herein are methods and compositions for treating disease-states associated with presence of increased number of ErbB4+ pro-inflammatory macrophages in a subject in need thereof. The methods include providing an activator of ErbB4 and administering a therapeutically effective amount of the activator to the subject. The compositions include an activator of ErbB4. In one embodiment, the activation of ErbB4 is Neuregulin-4.

Abstract: The invention provides compositions and methods for delivering carbon monoxide (CO) to subjects suffering from inflammatory, cardiovascular, Sickle Cell, and other disease. The compositions are liquids, including Newtonian and non-Newtonian liquids, such as pastes, gels, foams, emulsions, and other non-gaseous compositions, in which CO is dissolved at an amount that, when administered to a patient, provides a therapeutically or prophylactically effective amount of CO to the patient. The compositions can be provided in many forms, including in bottles or cans.

Abstract: Provided herein are compositions and methods for treating cancer in a subject in need thereof. The methods include using hybrid polymerized liposomal nanoparticles comprising, both polymerizable lipids and non-polymerizable lipids. The nanoparticles further comprise targeting agents and therapeutic agents.

Abstract: The present invention provides a fully intrathoracic artificial pacemaker. The pacemaker is of sufficiently compact size to allow for implantation of both the electrode and the power source within the chest cavity. In exemplary embodiments, a screw-type electrode is used for connection to heart tissue, and a relatively short lead is used to connect the electrode to a battery unit, which can comprise electronics for control of the pacemaker. An assembly for implanting the pacemaker, as well as methods of implanting the pacemaker, are disclosed. In embodiments, the device is designed as a fetal pacemaker.

Abstract: Provided herein are compositions and methods for treating cancer in a subject in need thereof. The methods include using hybrid polymerized liposomal nanoparticles comprising, both polymerizable lipids and non-polymerizable lipids. The nanoparticles further comprise targeting agents and therapeutic agents.

Abstract: The present disclosure is directed to sulfonic esters of metal oxides including those of formulas I and II:

Abstract: A method for controlling bleeding from bones, comprising the use of copolymers of oxyethylene and oxypropylene or mixtures thereof to cover the bleeding portions of bones. The copolymers are resorbable by the body, not metabolized, simple to prepare, inexpensive, readily available, and do not interfere with the fusion, osteogenesis, and related tissue healing and repair of the affected bones.

Abstract: The present invention is directed to sulfonic esters of metal oxides including those of formulas I and II:

Abstract: The invention relates to a novel drug delivery vehicle. Various embodiments of the invention provide a hybrid polymerized liposomal nanoparticle comprising both polymerizable lipids and non-polymerizable lipids. Therapeutic agents can be loaded into the polymerized liposomal nanoparticle and targeting agents can be conjugated to the surface of the polymerized liposomal nanoparticle. Also described in the invention are methods, compositions and kits that utilize the hybrid polymerized liposomal nanoparticle to treat disease conditions such as various cancers.

Abstract: The invention relates methods of using a retinoid agonist and a G-CSF or an analog thereof to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of a condition in a subject. The retinoid agonist and the G-CSF or the analog thereof may be provided in a single composition or in separate compositions. A therapeutically effective amount of the retinoid agonist and the G-CSF or the analog thereof may be administered to the subject concurrently or sequentially. Conditions treatable with the methods and compositions include but are not limited to various forms of neutropenia and microbial infections. The invention also relates to methods for determining the efficacy of the treatments described herein.

Abstract: The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of ErbB4.

Abstract: Described herein are methods for treating hematological malignancies and/or solid tumors in a subject using inhibitors of integrin alpha 6. In some embodiments, the inhibitors are monoclonal antibodies. The antibodies may be conjugated to additional therapeutic agents. The antibodies may be co-administered sequentially or simultaneously with additional therapeutic agents.